GeneDx Holdings WGS Fair Value Adjustment Of Warrants
Fair Value Adjustment Of Warrants at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about GeneDx Holdings's fair value adjustment of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GeneDx Holdings's fair value adjustment of warrants?
- GeneDx Holdings (WGS) reported fair value adjustment of warrants of -$2.54M in Q1 2026.
- How has GeneDx Holdings's fair value adjustment of warrants changed year-over-year?
- GeneDx Holdings's fair value adjustment of warrants decreased by 330.9% year-over-year, from $1.1M to -$2.54M.
- What is the long-term trend for GeneDx Holdings's fair value adjustment of warrants?
- Over 3 years (2021 to 2024), GeneDx Holdings's fair value adjustment of warrants has grown at a 14.9% compound annual growth rate (CAGR), from -$8.81M to $13.37M.
- What does fair value adjustment of warrants mean?
- This represents the non-cash gain or loss resulting from the periodic revaluation of outstanding warrant liabilities. Changes in the fair value of these instruments are driven by fluctuations in the company's stock price and volatility, impacting reported net income without affecting cash flow.